IRF4: Immunity. Malignancy! Therapy?

156Citations
Citations of this article
135Readers
Mendeley users who have this article in their library.

Abstract

IRF4, a member of the Interferon Regulatory Factor (IRF) family of transcription factors, is expressed in cells of the immune system, where it transduces signals from various receptors to activate or repress gene expression. IRF4 expression is a key regulator of several steps in lymphoid-, myeloid-, and dendritic-cell differentiation, including the differentiation of mature B cells into antibody-secreting plasma cells. IRF4 expression is also associated with many lymphoid malignancies, with recent evidence pointing to an essential role in multiple myeloma, a malignancy of plasma cells. Interference with IRF4 expression is lethal to multiple myeloma cells, irrespective of their genetic etiology, making IRF4 an "Achilles' heel" that may be exploited therapeutically. ©2009 American Association for Cancer Research.

Cite

CITATION STYLE

APA

Shaffer, A. L., Tolga Emre, N. C., Romesser, P. B., & Staudt, L. M. (2009, May 1). IRF4: Immunity. Malignancy! Therapy? Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-08-1845

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free